Scottish Radiological Society Spring Meeting 2021 May 14, 2021 09:00 AM - 05:00 PM — Virtual Meeting (online)
9th Annual Scottish Radiotherapy Research Forum Jun 03, 2021 12:30 PM - 05:00 PM — Virtual Meeting (online)
Medical Imaging Convention [rescheduled] Sep 15, 2021 - Sep 16, 2021 — National Exhibition Centre, Birmingham, England
Total Body PET 2021 conference [rescheduled] Sep 25, 2021 - Sep 27, 2021 — McEwan Hall, University of Edinburgh

eLearning

SINAPSE experts from around Scotland have developed ten online modules designed to explain medical imaging. They are freely available and are intended for non-specialists.


Edinburgh Imaging Academy at the University of Edinburgh offers the following online programmes through a virtual learning environment:

Neuroimaging for Research MSc/Dip/Cert

Imaging MSc/Dip/Cert

PET-MR Principles & Applications Cert

Applied Medical Image Analysis Cert

Online Short Courses

High-dose allopurinol reduces left ventricular mass in patients with ischemic heart disease

Author(s): S. Rekhraj, S. J. Gandy, B. R. Szwejkowski, M. A. Nadir, A. Noman, J. G. Houston, C. C. Lang, J. George, A. D. Struthers

Abstract:
OBJECTIVES: This study sought to ascertain if high-dose allopurinol regresses left ventricular mass (LVM) in patients with ischemic heart disease (IHD). BACKGROUND: LV hypertrophy (LVH) is common in patients with IHD including normotensive patients. Allopurinol, a xanthine oxidase inhibitor, has been shown to reduce LV afterload in IHD and may therefore also regress LVH. METHODS: A randomized, double-blind, placebo-controlled, parallel group study was conducted in 66 patients with IHD and LVH, comparing 600 mg/day allopurinol versus placebo therapy for 9 months. The primary outcome measure was change in LVM, assessed by cardiac magnetic resonance imaging (CMR). Secondary outcome measures were changes in LV volumes by CMR, changes in endothelial function by flow-mediated dilation (FMD), and arterial stiffness by applanation tonometry. RESULTS: Compared to placebo, allopurinol significantly reduced LVM (allopurinol -5.2 +/- 5.8 g vs. placebo -1.3 +/- 4.48 g; p = 0.007) and LVM index (LVMI) (allopurinol -2.2 +/- 2.78 g/m(2) vs. placebo -0.53 +/- 2.5 g/m(2); p = 0.023). The absolute mean difference between groups for change in LVM and LVMI was -3.89 g (95% confidence interval: -1.1 to -6.7) and -1.67 g/m(2) (95% confidence interval: -0.23 to -3.1), respectively. Allopurinol also reduced LV end-systolic volume (allopurinol -2.81 +/- 7.8 mls vs. placebo +1.3 +/- 7.22 mls; p = 0.047), improved FMD (allopurinol +0.82 +/- 1.8% vs. placebo -0.69 +/- 2.8%; p = 0.017) and augmentation index (allopurinol -2.8 +/- 5.1% vs. placebo +0.9 +/- 7%; p = 0.02). CONCLUSIONS: High-dose allopurinol regresses LVH, reduces LV end-systolic volume, and improves endothelial function in patients with IHD and LVH. This raises the possibility that allopurinol might reduce future cardiovascular events and mortality in these patients. (Does a Drug Allopurinol Reduce Heart Muscle Mass and Improve Blood Vessel Function in Patients With Normal Blood Pressure and Stable Angina?; ISRCTN73579730).

Full version: Available here

Click the link to go to an external website with the full version of the paper


ISBN: 1558-3597 (Electronic) 0735-1097 (Linking)
Publication Year: 2013
Periodical: J Am Coll Cardiol
Periodical Number: 9
Volume: 61
Pages: 926-32
Author Address: Division of Cardiovascular and Diabetes Medicine, Medical Research Institute, University of Dundee, Ninewells Hospital and Medical School, Dundee, Scotland, United Kingdom.